We have studied the expression of cytokine receptors CD25 (IL-2R alpha, 55
kD), CD116 (hGM-CSFR, 145 kD), CD117 (CSFR, 145 kD), CD120a (TNFR, 55 kD),
CD120b (TNFR, 75 kD), CD121a (IL-1R, type I, 80 kD), CDw123 (IL-3R), CD124
(IL-4R, 140 kD), CD126 (IL-6R, 80 kD), CD127 (IL-7R, 75 kD), CDw128 (IL-8R)
, CD130 (gp130 subunit), CDw131 (common beta), CD132 (IL-2R gamma), CD134 (
OX40) and also CD95 (Fas antigen) on the lymphoid leukaemic cells. Cells fr
om peripheral blood or bone marrow of 24 patients with disorders in lymphoi
d lineage mostly included acute lymphoid leukaemias (with a high leukocyte
count and percentage of blasts) were analysed for the expression of surface
membrane molecules by the immunofluorescence method evaluated by flow cyto
metry. The findings indicate that some monoclonal antibodies have a reactiv
ity against cytokine receptors of pathological cells in individual cases, b
ut with very variable qualitative and quantitative expression (number copie
s/cell). The lymphoid leukaemic cells demonstrate unique cytokine receptor
profiles, which reveal the great diversity of immunophenotypes within the m
ain functional characterisation of T and B lymphoproliferative malignancies
.